Month: August 2020

Gilead Sciences, Inc (NASDAQ: GILD) announced Monday it was seeking complete Food and Drug Administration approval for its drug Remdesivir, which is being used in the treatment of COVID-19.What Happened The drugmaker said it has filed a New Drug Application with the FDA on the basis of two randomized, open-label, multi-center Phase 3 clinical studies conducted by itself, and one other study by Anthony Fauci-led National Institute of Allergy and Infectious Diseases.The company claims the drug led to faster recovery from COVID-19 compared to placebo, and a 5-to-10-day treatment led to clinical improvements. Gilead noted that the drug was well-tolerated …read more […]

The coronavirus-fueled stock market sell-off in March didn’t prevent workers from piling money into their nest eggs, according to a new study from Fidelity Investments. …read more […]

Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.Coronavirus Vaccine Update: The Pennsylvania-based drugmaker had previously estimated it would begin the phase two and three trials during summer this year.Inovio said during the earnings call it was exploring partnerships beyond the United States and Europe for its vaccine candidate, and expected repetitive revenue similar to those from the flu vaccine.The company reiterated its previous estimate of producing one million doses this year and 100 million by 2021, and said it planned to obtain …read more […]

The company’s share price has soared, helping to boost the personal wealth of its chief executive. …read more […]

Occidental, which borrowed heavily to finance last year’s $38 billion purchase of rival Anadarko Petroleum, cut the value of its oil and gas properties by $6.6 billion, joining BP, Chevron and Total in massive write-downs as the industry now expects energy prices to stay low for years. Its oil and gas production will fall 13% this quarter over last, and another 5% in the fourth quarter, to 1.16 million barrels of oil and gas per day, the company said. In the Permian, where it became the largest operator through the Anadarko purchase, shale output will drop 37% this …read more […]

…read more […]

Vaccine specialist Vaxart (VXRT) reported 2Q20 earnings last week, but since its vaccine candidates are all in development, the results themselves were of little importance. More pertinent for investors were updates on the pipeline’s progress. Specifically, Vaxart’s COVID-19 oral vaccine candidate.As the only oral vaccine to be selected for inclusion in the government’s Operation Warp Speed (OWS) program, Vaxart’s offering has shown promise in pre-clinical trials, with a Phase 1 study expected to begin sometime in 2H20.While Vaxart’s incredible rise this year (shares are up by over 2,500%) has been solely COVID-driven, the company has other vaccines in development. These …read more […]

Working from home is the new normal. In The War Room, members have been cashing in regularly on stay-at-home companies like Peloton and Teladoc Health. Now, we’re not going to win every time with these short-term plays, but our track record speaks for itself. And on Peloton, Bryan has won 70% of the time!
Now let’s get back to today’s Trade of the Day…
Members just took profits with a sweet covered call trade on Herman Miller (Nasdaq: MLHR).

I mentioned the company in a previous issue a few weeks ago when we made the play.
Here’s what some members said…
“Sold separately. In the …read more […]

Gold seems to make headlines every day now that it is trading at all-time highs. Silver has been skyrocketing too.
If you don’t own any gold or silver, should you buy some now? If you do already own some, should you buy more?
I’ve never been a gold bug. You’re supposed to own gold for a number of reasons, including having it as a store of value when the spit hits the fan.
However, my thoughts on gold were formulated by talking to family members who were in Europe during World War II. Gold did not come close to holding its value during …read more […]

…read more […]

The narrative surrounding COVID-19-focused pharma companies is developing a new tone. While none of the players involved in the race to bring a vaccine to market have reached the final regulatory hurdles just yet, progress is being made with several Phase 3 trials already taking place.The talk is now centered around the issue of pricing – how much each company plans to sell its vaccine for.On the clinical trial front, mRNA vaccine maker Moderna (MRNA) is among the pack’s leaders. A Phase 3 clinical trial for mRNA-1273, its COVID-19 vaccine candidate, kicked off last week and data should be published …read more […]

(Bloomberg) — Occidental Petroleum Corp. reported a $6.6 billion writedown in the second quarter, equivalent to more than 40% of its market value, as the collapse in energy prices took its toll on the debt-laden U.S. shale oil producer.More than two-thirds of the impairment was to account for the lower value of its domestic onshore acreage, with the remainder in the Gulf of Mexico and overseas, the Houston-based company said Monday in a statement. The shares fell 3.6% at 5:02 p.m. in after-market trading in New York.Occidental is not alone is taking large impairments after the Covid-19 pandemic crushed demand …read more […]

Tech stocks are on the rise. As the world continues to face a pandemic, our attention has turned to technology more than ever. Trend Expert Matthew Carr explains how investors can benefit.
Our world is moving quicker than ever before.
A couple of weeks ago, I wrote about E.M. Rogers’ “Diffusion of Innovation” theory. It lays out how a new technology moves from introduction to complete saturation.
But there’s another aspect of this theory that investors (and society in general) must come to terms with: Technology is being adopted more rapidly than ever before.
It used to take decades for a technological innovation to …read more […]

Canopy Growth shares jumped nearly 8% after its latest results showed a narrower than expected loss and a hot start for its cannabis beverages. …read more […]

…read more […]